160 related articles for article (PubMed ID: 9551898)
1. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity.
Morgan DJ; Kreuwel HT; Fleck S; Levitsky HI; Pardoll DM; Sherman LA
J Immunol; 1998 Jan; 160(2):643-51. PubMed ID: 9551898
[TBL] [Abstract][Full Text] [Related]
2. Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration.
Janicki CN; Jenkinson SR; Williams NA; Morgan DJ
Cancer Res; 2008 Apr; 68(8):2993-3000. PubMed ID: 18413769
[TBL] [Abstract][Full Text] [Related]
3. Adoptive transfer enables tumor rejection targeted against a self-antigen without the induction of autoimmunity.
Eck SC; Turka LA
Cancer Res; 2001 Apr; 61(7):3077-83. PubMed ID: 11306490
[TBL] [Abstract][Full Text] [Related]
4. Influenza A virus-specific H-2d restricted cross-reactive cytotoxic T lymphocyte epitope(s) detected in the hemagglutinin HA2 subunit of A/Udorn/72.
Saikh KU; Martin JD; Nishikawa AH; Dillon SB
Virology; 1995 Dec; 214(2):445-52. PubMed ID: 8553546
[TBL] [Abstract][Full Text] [Related]
5. Role of a subdominant H-2Kd-restricted SV40 tumor antigen cytotoxic T lymphocyte epitope in tumor rejection.
Newmaster RS; Mylin LM; Fu TM; Tevethia SS
Virology; 1998 May; 244(2):427-41. PubMed ID: 9601511
[TBL] [Abstract][Full Text] [Related]
6. Development of a murine mutant Ras CD8+ CTL peptide epitope variant that possesses enhanced MHC class I binding and immunogenic properties.
Bristol JA; Schlom J; Abrams SI
J Immunol; 1998 Mar; 160(5):2433-41. PubMed ID: 9498787
[TBL] [Abstract][Full Text] [Related]
7. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors.
Toes RE; Blom RJ; Offringa R; Kast WM; Melief CJ
J Immunol; 1996 May; 156(10):3911-8. PubMed ID: 8621930
[TBL] [Abstract][Full Text] [Related]
8. Antigen concentration and precursor frequency determine the rate of CD8+ T cell tolerance to peripherally expressed antigens.
Morgan DJ; Kreuwel HT; Sherman LA
J Immunol; 1999 Jul; 163(2):723-7. PubMed ID: 10395663
[TBL] [Abstract][Full Text] [Related]
9. Peripheral tolerance to an islet cell-specific hemagglutinin transgene affects both CD4+ and CD8+ T cells.
Lo D; Freedman J; Hesse S; Palmiter RD; Brinster RL; Sherman LA
Eur J Immunol; 1992 Apr; 22(4):1013-22. PubMed ID: 1348026
[TBL] [Abstract][Full Text] [Related]
10. Class I MHC-restricted recognition of cells expressing a gene encoding a 41 amino acid product of the influenza hemagglutinin.
Sweetser MT; Braciale VL; Braciale TJ
J Immunol; 1988 Nov; 141(10):3324-8. PubMed ID: 2460530
[TBL] [Abstract][Full Text] [Related]
11. The weak CD8+ CTL response to an influenza hemagglutinin epitope reflects limited T cell availability.
Cao W; Myers-Powell BA; Braciale TJ
J Immunol; 1996 Jul; 157(2):505-11. PubMed ID: 8752895
[TBL] [Abstract][Full Text] [Related]
12. Generation of cytotoxic T-lymphocytes to a self-peptide/class I complex: a model for peptide-mediated tumor rejection.
Tjoa BA; Kranz DM
Cancer Res; 1994 Jan; 54(1):204-8. PubMed ID: 7505197
[TBL] [Abstract][Full Text] [Related]
13. Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice.
Tao P; Luo M; Pan R; Ling D; Zhou S; Tien P; Pan Z
Antiviral Res; 2009 Mar; 81(3):253-60. PubMed ID: 19135483
[TBL] [Abstract][Full Text] [Related]
14. Alloreactive T cells that do not require TCR and CD8 coengagement are present in naive mice and contribute to graft rejection.
Smith PA; Potter TA
J Immunol; 1998 Jun; 160(11):5382-9. PubMed ID: 9605138
[TBL] [Abstract][Full Text] [Related]
15. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors.
Marzo AL; Lake RA; Robinson BW; Scott B
Cancer Res; 1999 Mar; 59(5):1071-9. PubMed ID: 10070965
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo.
Gritzapis AD; Mahaira LG; Perez SA; Cacoullos NT; Papamichail M; Baxevanis CN
Cancer Res; 2006 May; 66(10):5452-60. PubMed ID: 16707474
[TBL] [Abstract][Full Text] [Related]
17. The immunologic function of 1B2+ double negative (CD4-CD8-) T cells in the 2C transgenic mouse.
Margenthaler JA; Flye MW
J Surg Res; 2005 Jun; 126(2):160-6. PubMed ID: 15919414
[TBL] [Abstract][Full Text] [Related]
18. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo.
Prévost-Blondel A; Zimmermann C; Stemmer C; Kulmburg P; Rosenthal FM; Pircher H
J Immunol; 1998 Sep; 161(5):2187-94. PubMed ID: 9725210
[TBL] [Abstract][Full Text] [Related]
19. A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL.
Matsui S; Ahlers JD; Vortmeyer AO; Terabe M; Tsukui T; Carbone DP; Liotta LA; Berzofsky JA
J Immunol; 1999 Jul; 163(1):184-93. PubMed ID: 10384115
[TBL] [Abstract][Full Text] [Related]
20. Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model.
Fernando GJ; Stewart TJ; Tindle RW; Frazer IH
J Immunol; 1998 Sep; 161(5):2421-7. PubMed ID: 9725239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
